YAP/TAZ activation is sufficient to lead to cancers in mice, such as hepatocellular carcinoma and cholangiocarcinoma (Dong et al. 2007, Yimlamai et al. 2014, Zhou et al. 2009), rhabdomyosarcoma (Tremblay et al. 2014), uveal melanoma (Li et al. 2019), and malignant peripheral nerve sheath tumors (Wu et al. 2018). The gene discussed is TAFAZZIN; the disease is hepatocellular carcinoma.